Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 6/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL299666 | 0.89 | MEN1 (0.47) | MEN1KMT2ATDP1MAPTALDH1A1 | |
| SCHEMBL294292 | 0.88 | MEN1 (0.46) | MEN1KMT2ATDP1MAPTALDH1A1 | |
| SCHEMBL294568 | 0.87 | MEN1 (0.47) | MEN1KMT2ATDP1MAPTALDH1A1 | |
| SCHEMBL294745 | 0.82 | MEN1 (0.47) | MEN1KMT2ATDP1MAPTALDH1A1 | |
| SCHEMBL366822 | 0.77 | ALDH1A1 (0.44) | MEN1KMT2ATDP1MAPTALDH1A1 | |
| SCHEMBL295828 | 0.76 | KMT2A (0.51) | MEN1KMT2ATDP1MAPTALDH1A1 | |
| SCHEMBL295829 | 0.76 | KMT2A (0.51) | MEN1KMT2ATDP1MAPTALDH1A1 | |
| SCHEMBL295821 | 0.75 | SMN1; SMN2 (0.47) | MEN1KMT2ATDP1MAPTALDH1A1 | |
| SCHEMBL294734 | 0.74 | MEN1 (0.50) | MEN1KMT2ATDP1MAPTALDH1A1 | |
| SCHEMBL3376873 | 0.73 | P2RX7 (0.42) | MEN1KMT2AALDH1A1P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344004-B2 | Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals | SANOFI (FR) | 2013-01-01 | — | — | US | disclosed |
| US-8344004-B2 | Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals | SANOFI (FR) | 2013-01-01 | — | — | US | disclosed |
| US-8344004-B2 | Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals | SANOFI (FR) | 2013-01-01 | — | — | US | disclosed |
| EP-2240474-B1 | CYCLIC PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2012-03-14 | — | — | EP | disclosed |
| US-20110224263-A1 | Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2011-09-15 | — | — | US | disclosed |
| US-20110224263-A1 | Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2011-09-15 | — | — | US | disclosed |
| US-20110224263-A1 | Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2011-09-15 | — | — | US | disclosed |
| EP-2240474-A1 | CYCLIC PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009080223-A1 | CYCLIC PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080223-A1 | CYCLIC PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224263-A1 | Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals | PPARD, PPARG, PPARA | MEN1 4666/4885KMT2A 3682/4885TDP1 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.